 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131132133 |
- everolimus / Generic mfg.
Enrollment change: RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 14, 2011
P2, N=7, Terminated, Sponsor: Case Comprehensive Cancer Center
N=33 --> 7
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Nov 9, 2011
P1, N=53, Recruiting, Sponsor: Emory University
- | New P4 trial: CONCERVIC: Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (clinicaltrials.gov) - Nov 8, 2011
P4, N=30, Recruiting, Sponsor: Irmandade Santa Casa de Misericórdia de Porto Alegre
- | Simulect (basiliximab) / Novartis
New P2 trial, Combination therapy: Pharmacodynamics, Efficacy, Safety of Basiliximab 40 or 80 mg Combined With CsA or Everolimus, in Low Risk de Novo Renal Transplant Recipients (clinicaltrials.gov) - Nov 8, 2011
P2, N=50, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Signifor (pasireotide) / Recordati
New P1/2 trial: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 8, 2011
P1/2, N=49, Recruiting, Sponsor: Emory University
- everolimus / Generic mfg.
New P2 trial: Everolimus in Refractory Testicular Germ Cell Cancer (clinicaltrials.gov) - Nov 3, 2011
P2, N=38, Recruiting, Sponsor: National Cancer Institute, Slovakia
- cyclophosphamide / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer (clinicaltrials.gov) - Oct 31, 2011
P1/2, N=96, Recruiting, Sponsor: Hans J. van der Vliet, MD, PhD
N=33 --> 7 Not yet recruiting --> Recruiting
- Campath (alemtuzumab) / Sanofi
Enrollment open: Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection (clinicaltrials.gov) - Oct 30, 2011
P1/2, N=30, Recruiting, Sponsor: The Russian State Medical University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg.
New P1/2 trial, Metastases: Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer (clinicaltrials.gov) - Oct 27, 2011
P1/2, N=96, Recruiting, Sponsor: Hans J. van der Vliet, MD, PhD
- | everolimus / Generic mfg.
New P1/2 trial, Combination therapy: Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Oct 16, 2011
P1/2, N=125, Recruiting, Sponsor: University of Cologne
- | everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment open: AIO-STO-0111: A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (clinicaltrials.gov) - Oct 16, 2011
P3, N=480, Recruiting, Sponsor: Krankenhaus Nordwest
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 13, 2011
P2, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
New P4 trial: Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults (clinicaltrials.gov) - Oct 10, 2011
P4, N=30, Not yet recruiting, Sponsor: Deise de Boni Monteiro de Carvalho
- everolimus / Generic mfg.
Trial termination, PARP Biomarker, IO biomarker: Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas (clinicaltrials.gov) - Oct 10, 2011
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Novartis terminated funding
- ||| Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer (clinicaltrials.gov) - Oct 5, 2011
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; Novartis terminated funding Active, not recruiting --> Completed
- imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Oct 3, 2011
P2, N=23, Completed, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=43 --> 23
- imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Oct 3, 2011
P2, N=23, Completed, Sponsor: OHSU Knight Cancer Institute
N=43 --> 23 Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
New P1/2 trial: Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection (clinicaltrials.gov) - Oct 2, 2011
P1/2, N=30, Recruiting, Sponsor: The Russian State Medical University
- | Herceptin (trastuzumab) / Roche
Enrollment open, Combination therapy: A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases (clinicaltrials.gov) - Oct 2, 2011
P2, N=35, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial completion, Monotherapy, Metastases: RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment (clinicaltrials.gov) - Sep 27, 2011
P2, N=54, Completed, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| apitolisib (GDC-0980) / Roche
New P2 trial, Metastases: Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy (clinicaltrials.gov) - Sep 26, 2011
P2, N=85, Active, not recruiting, Sponsor: Genentech
- ||| Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: RECORD-3: Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Sep 18, 2011
P2, N=470, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- temozolomide / Generic mfg., everolimus / Generic mfg.
Trial completion: Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme (clinicaltrials.gov) - Sep 18, 2011
P1, N=32, Completed, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Farydak (panobinostat) / Secura Bio
Enrollment change, Metastases: Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors (clinicaltrials.gov) - Sep 13, 2011
P1, N=14, Completed, Sponsor: Herbert Hurwitz
Active, not recruiting --> Completed N=100 --> 14
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: COBRA: Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. (clinicaltrials.gov) - Sep 13, 2011
P1, N=32, Completed, Sponsor: Herbert Hurwitz
N=100 --> 14 N=150 --> 32
- | everolimus / Generic mfg., sorafenib / Generic mfg.
New P1/2 trial: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) - Sep 13, 2011
P1/2, N=118, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||||| Simulect (basiliximab) / Novartis
Trial completion: Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids (clinicaltrials.gov) - Sep 12, 2011
P3, N=122, Completed, Sponsor: Novartis
N=150 --> 32 Recruiting --> Completed
- Enrollment closed: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (clinicaltrials.gov) - Sep 8, 2011
P2, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Trial termination: REVERT: Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection (clinicaltrials.gov) - Sep 7, 2011
P2, N=43, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Terminated
- Votrient (pazopanib) / Novartis, BeiGene
New P1 trial, Metastases: Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (clinicaltrials.gov) - Sep 6, 2011
P1, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| retaspimycin (IPI-504) / Infinity Pharma
New P1/2 trial, Combination therapy: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 31, 2011
P1/2, N=70, Active, not recruiting, Sponsor: Infinity Pharmaceuticals, Inc.
- | everolimus / Generic mfg.
New P2 trial: EPOCAL: Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study (clinicaltrials.gov) - Aug 24, 2011
P2, N=117, Recruiting, Sponsor: Azienda Ospedaliera di Padova
- everolimus / Generic mfg.
New P2 trial: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) - Aug 16, 2011
P2, N=25, Active, not recruiting, Sponsor: New York University School of Medicine
- everolimus / Generic mfg.
Trial withdrawal, Surgery: Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 10, 2011
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated Terminated --> Withdrawn
- everolimus / Generic mfg.
Enrollment change, PARP Biomarker, IO biomarker: Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas (clinicaltrials.gov) - Aug 9, 2011
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Terminated --> Withdrawn N=40 --> 2
- everolimus / Generic mfg.
Trial termination: Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 8, 2011
P1/2, N=5, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Terminated; Terminated due to low accrual. Study was closed to accrual prematurely and did not continue on to Phase II.
- | everolimus / Generic mfg.
New P2 trial, Monotherapy, Surgery: NFitor: Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (clinicaltrials.gov) - Aug 7, 2011
P2, N=32, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- everolimus / Generic mfg.
New P2 trial, P2 data: A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=11, Terminated, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France